Recursion Pharmaceuticals RXRX, a TechBio company that decodes biology and chemistry to industrialize drug discovery, is ...

Mixture-of-Recursions (MoR) is a new AI architecture that promises to cut LLM inference costs and memory use without sacrificing performance.

According to the study, supply chain data governance is not just a technological necessity but a foundational enabler of ...

AI-native pharma disruptors like Palantir, Tempus, and Recursion are reshaping medicine. But ETFs still favor old-school ...

Early intervention in psoriatic arthritis (PsA) is disease-modifying, and delays in diagnosis, even by 6 months, can reduce ...

Earlier this month, venture capitalist and OpenAI backer Geoff Lewis posted an alarming video on X-formerly-Twitter, ...

For India, the stakes are especially high. Startups such as Gan.ai, Gnani.ai and Soket AI Labs, selected to build foundation models under the IndiaAI Mission, face a unique challenge: how to curate cl ...

As AI gets more curious, security gaps widen. Explore the risks of prompt exfiltration and autonomous model behavior.

In an industry where 90 percent of drug candidates fail before reaching the market, a handful of startups are betting ...

The modern enterprise analytics landscape resembles a bustling financial district at rush hour—valuable data moving at lightning speed between towering infrastr ...

AI-led drug for chronic lung disease set to enter phase 3 clinical trials, though experts remain divided on AI's impact in ...

Discover how self-improving AI systems are redefining innovation, reshaping industries, and challenging our understanding of ...